Drugs / ABX196
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03897543 | Aug 2019 → Jun 2021 overdue | hepatocellular carcinoma | Abivax S.A. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-01-19 | Abivax S.A. | Results Abivax phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21 at ASCO GI Cancers Symposium 2022 abivax.com ↗
Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces today the detailed results of the dose escalation phase of its clinical phase 1/2 study conducted with ABX196 for the treatment of hepatocellular carcinoma (HCC), to be presented at the ASCO GI Cancers Symposium on January 20-22, 2022. |
| 2021-11-30 | Abivax S.A. | Results Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium 2022 abivax.com ↗ |
| 2019-05-13 | Abivax S.A. | Regulatory Abivax and Scripps Research Announce FDA Approval to Initiate a Phase 1/2 Clinical Trial with ABX196 in Patients with Hepatocellular Carcinoma abivax.com ↗ |
| 2017-10-12 | Abivax S.A. | Results ABIVAX presents novel data on the efficacy of its immune enhancer ABX196 in animal model of liver cancer at the World Vaccine Congress abivax.com ↗
A similar beneficial effect was seen for survival at day 61: control group: 31% sorafenib: 42% (p=ns), anti-PD-1: 92% (p,0.01), ABX196: 92% (p<0.01), and the combination of ABX196 and anti-PD-1: 100% (p<0.001). |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABX196 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03897543 ↗ |
| Known as | PBS 96 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594427 ↗ |
| Modality | Small molecule | — CHEMBL4594427 ↗ |
| Route | Intramuscular | “IM injection” NCT03897543 ↗ |